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Abstract
Volume of distribution and fraction unbound are two key parameters in pharmacokinetics. The fraction unbound describes
the portion of free drug in plasma that may extravasate, while volume of distribution describes the tissue access and
binding of a drug. Reliable in silico predictions of these pharmacokinetic parameters would benefit the early stages of drug
discovery, as experimental measuring is not feasible for screening purposes. We have applied linear and nonlinear
multivariate approaches to predict these parameters: linear partial least square regression and non-linear recursive
partitioning classification. The volume of distribution and fraction of unbound drug in plasma are predicted in parallel
within the model, since the two are expected to be affected by similar physicochemical drug properties. Predictive models
for both parameters were built and the performance of the linear models compared to models included in the commercial
software Volsurf+. Our models performed better in predicting the unbound fraction (Q2 0.54 for test set compared to 0.38
with Volsurf+ model), but prediction accuracy of the volume of distribution was comparable to the Volsurf+ model (Q2 of
0.70 for test set compared to 0.71 with Volsurf+ model). The nonlinear classification models were able to identify
compounds with a high or low volume of distribution (sensitivity 0.81 and 0.71, respectively, for test set), while classification
of fraction unbound was less successful. The interrelationship between the volume of distribution and fraction unbound is
investigated and described in terms of physicochemical descriptors. Lipophilicity and solubility descriptors were found to
have a high influence on both volume of distribution and fraction unbound, but with an inverse relationship.
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Introduction
The extent of drug distribution determines the access of a drug
to its sites of action and to other tissues, which might give rise to
adverse effects. A primary parameter for drug distribution is the
volume of distribution (Vd) that is defined as.
Vd~
A
C
where A is the amount of drug in the body, and C is the drug
concentration in plasma (both free drug and protein-bound drug).
Volume of distribution is an apparent volume that increases with
elevated drug binding in the extravascular space of the body and
not an anatomically defined volume. Consequently, extensive drug
binding outside the blood vessels leads to increasing values of A/C
ratio. As tissue binding of drugs varies considerably, volume of
distribution displays a wide range of values. For example,
erythropoietin is confined to the vascular space presenting a Vd
of 4 L (approximately the anatomical volume of vascular space)
[1], while hydroxychloroquine with a Vd of 49 000 L strongly
accumulates into the cells and tissues [2]. Volume of distribution at
steady state (Vss) is measured at equilibrium, therefore, it describes
the molecular tissue binding more reliably than other volume of
distribution parameters that are dependent on the time after
measurement. Vss depends on the access of the drug to the cells
and tissues, its affinity to plasma proteins and tissue components,
and number of binding sites in plasma and tissues.
Drug concentration in plasma (C) includes both unbound (Cu) and
protein-bound drug in plasma. However, only the fraction of free
drug in plasma permeates across the cellular membranes and vascular
walls in most tissues. The free fraction of drug in plasma (fu) is
described by the ratio Cu/C. Likewise the drug in the tissues also
includes both free (CuT) or tissue bound parts. The unbound fraction
of drug in tissues is: fuT = CuT/CT, where CT is the total drug
concentration in the tissue. Drug binding to plasma proteins and
tissue components influences drug partitioning between the tissues
and plasma. Thus, Vss can be presented using the following equation:
Vss~VpzVT1
fu
fuT1
 !
zVT2
fu
fuT2
 !
::::
PLOS ONE | www.plosone.org 1 October 2013 | Volume 8 | Issue 10 | e74758
where Vp is the anatomical volume of plasma and VT is the true
anatomical volume of each tissue. Vss depends on the anatomical
volumes of the tissues, and the relative extent of drug binding in the
plasma and tissues described as fu/fuT ratios.
As volume of distribution describes the extent of drug
distribution, it is important to predict its value early in drug
development before experimental measuring in humans. Vss in
humans may be extrapolated from the in vivo animal data that is
obtained during the drug discovery process, but computational
approaches are useful at early stages before animal data has been
collected. The volume of distribution used for computational
modeling should be collected from intravenous and not from oral
pharmacokinetics studies as in some cases [3], [4]. The benefit of
intravenous administration is the defined quantity of the drug that
is subject to distribution, which avoids the uncertainty associated
with incomplete bioavailability after extravascular administration.
Even though quantitative structure-property relationship
(QSPR) has been widely used for prediction of Vss [3–16], it
remains a challenging problem that has not been adequately
solved. The early attempts for predicting volume of distribution
were based on small data sets and did not specify the type of
volume of distribution that was used as the endpoint or in some
cases used several types of volume of distribution for the model
building [3-8], [11], [13], [14], [17]. In 2008, a major advance was
the publication of a clean, manually curated dataset of Vss [18]
that subsequently has been used successfully to build predictive
models for Vss [12], [16].
The main difference in the work presented here compared to
the previously published models of Vss is that we have included
another pharmacokinetic parameter, fu, to the modeled respons-
es. The fu in plasma depends on the binding affinity and capacity
of plasma proteins, which also affect the volume of distribution.
The fraction of unbound drug in plasma can be estimated
relatively easily in vitro, but computational models for predicting
fu are also available [19-21]. The VolSurf+ software includes
prediction tools for both volume of distribution and plasma
protein binding, however, there is limited information of the
methodology behind the models and their prediction capacity
have not been evaluated in an unbiased manner in the literature.
The two parameters, Vss and fu, are expected to be affected by
similar physicochemical drug properties and our hypothesis was
that modeling them in parallel would benefit their prediction. We
have applied both linear and nonlinear multivariate approaches:
linear partial least square (PLS) regression combined with
principal component analysis (PCA) and non-linear recursive
partitioning (RP) classification. RP has been shown to perform
well when dealing with complex endpoints associated with
multiple mechanisms, while PLS allows many responses (in our
case Vss and fu) to be incorporated in one regression model, but
to our knowledge, this approach has not been used previously in
pharmacokinetic QSPR modeling.
Materials and Methods
1. Data Set
The initial dataset collated by Obach and co-workers [18]
contains 670 compounds with Vss and fu values determined after
intravenous administration to healthy people. The collection steps,
the quality and the diversity of the data have been meticulously
detailed in the publication.
The 2D structures of the compounds were obtained from the
ACD/Dictionary version 11 [22] or the PubMed compound
database (http://www.ncbi.nlm.nih.gov/pccompound Accessed
2010 October). If the compounds were represented as salts in
the 2D structure, the counter ion was discarded. The 3D structures
were generated using Concord within SYBYL 8.0 [23]. A set of 648
drugs with both 2D and 3D structures were obtained. For the
remaining 22 compounds in Obach’s data set either a 2D structure
or minimized 3D structure was not obtained or it was not possible
to calculate descriptors from the structures. The Vss of artesunate
was corrected to 1.5 L/kg based on the work of White [24].
Furthermore, we excluded ibadronic, pamodronic, risedronic and
zoledronic bisphosphonates from the set, since these compounds
are sequestered to the bones, preventing their detection in the
plasma, and leading to underestimated values of Vss [25]. The
antimalarial drugs hydroxychloroquine and chloroquine have Vss
values of 700 L/kg and 140 L/kg, respectively. These values are
far beyond the range of other Vss values (0.035–60 L/kg) and they
were excluded to avoid biasing the model.
The final data set of 642 drugs (Figure 1) displays Vss values of
0.035–60 L/kg and fu values (541 drugs) of 0.0002–1.
2. Calculation of Molecular Descriptors
In this study, molecular descriptors were calculated using
ACDlabs [26], Volsurf+ [17] and MOE [27]. Input molecular
structures were two-dimensional for ACDlabs and three-dimen-
sional for Volsurf+ and MOE, for the later Gasteiger-Huckel
charges were added. Identical descriptors (i.e. molecular weight,
molecular volume) were excluded before combining descriptor sets
for modeling. The descriptors that were used for model building
are listed in Table 1 and the calculated descriptor values for the
data set are available in File S1.
3. PCA and PLS Regression Models
QSPR models were built using linear multivariate analysis tools
PCA and PLS (Simca plus Version 10.5) [28]. All descriptors were
transformed with unit variance scaling and mean centering before
PCA and PLS analysis. Moreover, the descriptors with a broad
range or unequal distribution across the range were logarithmi-
cally transformed to obtain better distributions. Three sets of
molecular descriptors were assembled for the regression modeling:
(1) ACDlabs descriptors and MOE logS descriptor; (2) VolSurf+
descriptors; (3) the combination of ACDlabs, MOE and VolSurf+
descriptors.
A workflow of the modeling process is presented in Figure 2.
Before modeling, a foreign set of 101 drugs was randomly
excluded from the final 642 compound set. The descriptor matrix
of the remaining 541 drugs was analysed with PCA to identify the
drugs that fall outside the general chemical space of the compound
set and descriptors that should be excluded from the model (model
calibration). Drugs that were outliers based on their distribution in
the PCA plot and whose descriptor values fell outside the
boundaries outlined in Table 2 were excluded. Based on the
scatter plot of the final PCA plot, an external test set (Figure 3) of
101 compounds representative of the chemical space was selected.
The external set comprises molecules within the chemical space of
the model, while the foreign set, which was selected before the
PCA and model calibration, also includes compounds outside the
chemical space used for model building. The remaining
compounds constitute the training set for the PLS model building
(365 drugs for model 1; 357 drugs for model 2; 361 drugs for
model 3). The training sets were used to build PLS models that
relate the descriptors to the two simultaneously modelled
responses, log Vss and fu. During initial stages of the analytical
process, the number of highly correlated variables observed in the
PLS weight plot was gradually reduced in order to equilibrate the
influence of the overall set of descriptors on the responses.
Subsequent models with improved statistic parameters were
Parallel Prediction of Vss and Fu for Drugs
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obtained and variables deemed least influential to the modelled
pharmacokinetic parameters were excluded. The decisions were
based on the PLS weight plot and confirmed by the variable
importance plot results. Moreover, the distribution of the drugs
was followed up by the PLS score and Dmod plots, in order to
detect outliers.
4. Recursive Partitioning Classification Models
A RP analysis was carried out using Discovery Studio version 3.5
(Accelrys Inc.) to develop decision trees that categorize the
compounds into classes that are based on the Vss values or both Vss
and fu values (Table 3 and 4). Volume of distribution is defined by
drug interactions with the main volumes in the body: extracellular
space and cellular tissue space. We used these anatomical volumes
as rough guidance to classify the volumes into three classes. Class 1
represents the volume of the extracellular fluid (0–0.3 L/Kg), class
2 represents Vss values that take into consideration distribution to
the tissues (0.3–1 L/Kg), and class 3 values of Vss represent
significant binding to the cellular components (.1 L/Kg).
However, it should be noted that Vss is an apparent volume that
does not strictly obey anatomical volumes, therefore the anatom-
ical distribution of the compounds cannot be concluded from the
Vss. Distribution of compounds into the three classes is shown in
Figure 1A. When both Vss and fu values were predicted, each class
Figure 1. Distribution of compounds in the data set. (A) The distribution of logVss values in the final dataset. Lines have been draw at 0.3 L/kg
and 1 L/kg to indicate the boundaries between the three classes used in the RP models. B) Distribution of compounds based on both log Vss and log
fu values and coloring by compound charge (basic-red, neutral-yellow, acidic-green, zwitterionic-blue).
doi:10.1371/journal.pone.0074758.g001
Table 1. The descriptors included in modeling.
ACDlabs descriptors Volsurf+ descriptors MOE descriptors
ALogD5 V WO1 CW5 POL %FU4 LgS6 logS
ALogD5.5 S WO2 CW6 MW %FU5 LgS6
ALogD7 R WO3 CW7 FLEX %FU6 LgS7
ALogD7.4 G WO4 CW8 FLEX_RB %FU7 LgS7.5
APSA W1 WO5 ID1 NCC %FU8 LgS8
HDonors W2 WO6 ID2 DIFF %FU9 LgS9
HAcceptors W3 WN1 ID3 LOGP n-Oct %FU10 LgS10
FRB W4 WN2 ID4 LOGP c-Hex DRDRDR LgS11
Rule Of 5 W5 WN3 CD1 PSA DRDRAC L0LgS
Molar Volume W6 WN4 CD2 HAS DRDRDO L1LgS
MW W7 WN5 CD3 PSAR DRACAC L2LgS
Surface Tension W8 WN6 CD4 PHSAR DRACDO L3LgS
Polarizability D1 IW1 CD5 LgD5 DRDODO L4LgS
C ratio D2 IW2 CD6 LgD6 ACACAC DD1
N ratio D3 IW3 CD7 LgD7 ACACDO DD2
NO ratio D4 IW4 CD8 LgD7.5 ACDODO DD3
Num Rings D5 CW1 HL1 LgD8 DODODO DD4
Num Ar Rings D6 CW2 HL2 LgD9 SOLY DD5
D7 CW3 A LgD10 LgS3 DD6
D8 CW4 CP AUS7.4 LgS4 DD7
LgS5 DD8
doi:10.1371/journal.pone.0074758.t001
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Table 2. Statistical parameters of the PCA models and the chemical boundaries chosen during the PCA modelling.
A R2X Q2X Criteria of model calibration
Model 1 7 0.90 0.58 MWa,940 PSAb,205 POLc,71 HBDd,10 HBAe,15 and -7.71,LogSf,0.38
Model 2 7 0.79 0.73 MW,940 WO4g,100 WO6,2 PSA,205 SOLYh,0.93 Vi,1353 POL,71 LogS9j,5.3 W4k,483
Model 3 7 0.79 0.72 MW,940 WO4,100 PSA,205 SOLY,0.93 MVl,466 Rule of 5,3
aMW:molecular weight; bPSA: polar surface area; cPOL: polarizability; dHBD: hydrogen bond donors; eHBA: hydrogen bond acceptors; fLogS: log of solubility; gWO4
andWO6: hydrogen bond donor volume at different energy levels; hSOLY: intrinsic solubility; iV:molecular volume; jLogS9: log of solubility at pH 9; kW4: hydrophilic
volume; lMV: molar volume.
doi:10.1371/journal.pone.0074758.t002
Figure 2. Flowchart of the work process to obtain regression and classification models for Vss and fu. MFE= mean fold error, SI
= Sensitivity, SPEC= specificity.
doi:10.1371/journal.pone.0074758.g002
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was further divided into compounds with low to intermediate
(,0.7) or high (.0.7) fu. Compounds with missing fu values were
addressed by assigning them the mean value of all fu values and
distributing them equally in the training and external test set,
which is a standard approach to handle missing values in RP
analysis. In our study, balanced forest of RP was used, since it is
the appropriate method for imbalanced data [29]. This type of RP
contains a relatively small number of trees (in average 10) using a
separate bootstrap sample of the original data for each tree. For
each tree, the number of members in all classes is equal to the
number of members in the smallest class. The number of
descriptors that was used as split criterion within each tree was
set to the square root of total descriptors. The weighing method
was set to ‘‘uniform’’ and the equalize class sizes to true. All others
parameters were set to default.
A training set was used to build the decision trees and an
external test set was utilized to evaluate the predictive power of the
models. To generate the training and external test set for RP
analyses, all compounds were first clustered by similarity based on
root mean square deviation and each cluster was divided into
training and test sets to ensure that both sets included compounds
from each cluster. The data set used to train the model consisted of
382 compounds, while 260 compounds were used as an external
test set (Figure 2).
5. Model validation
The prediction accuracy of the PLS models was determined by
internal and external validation. The internal validation is based
on the cross-validation value Q2Y (Q2) that is calculated by leaving
out 1/7 of the data, and predicting these compounds based on a
model trained by the remaining data. The external validation is
conducted with the external test set. The model was used to
predict the log Vss and fu of the external test set. The predicted
responses were plotted against the observed responses (i.e.
experimental Vss and fu). The R
2 value of the regression line for
the plot was considered as the Qe
2 (goodness of prediction of the
external test set).
We estimated the predictive ability of the RP classification
models using out-of-bag statistics. The external test set was used to
estimate the fitting ability of the model on a new dataset that was
not used in the model construction. The performance of the RP
models is based on three metrics: true positive rate (recall or
sensitivity), specificity, and the area under the curve (AUC) of the
receiver operating characteristics (ROC) plot [30]. AUC repre-
sents the probability that a classifier will be estimated correctly,
with values .0.5 indicating better than random prediction and 1
signifying perfect prediction. In the case of more than two classes
(multiclassification), a confusion matrix is a square of NxN, where
N is the number of classes. AUC is computed as defined by Hand
and Till (2001) as an average over components generated from
several ROC plots for a Y property and cannot be plotted [30].
For instance, when N (A, B, C) is 3, the classifier’s performance is
computed per class as follows for class A:
Figure 3. PCA score plot. The final PCA score plot obtained after model 3 calibration where the two principal components explain 27% and 20%,
respectively, of the variance in the data set. The open squares represent the drugs in the external test set and the filled triangles the drugs in the
training set. The ellipse depicts the 95% confidence region of the model (Hotelling T2).
doi:10.1371/journal.pone.0074758.g003
Table 3. Division of training and test set compounds into
three classes according to observed Vss.
Class 1 Class 2 Class 3 Total
Vss =0–0.3
L/kg
Vss =0.3–1
L/kg Vss .1 L/kg
Training 105 96 181 382
Test 62 71 127 260
Total 167 167 308 642
doi:10.1371/journal.pone.0074758.t003
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Actual=predicted ClassA ClassB ClassC
ClassA TA FB1 FC1
ClassB FA2 TB FC2
ClassC FA3 FB3 TC
Sensitvity~
TA
TAzFB1zFC1
Specificity~
TBzTC
TBzFA2zTCzFA3
6. Y-randomization test
In addition to the internal and external validation, the Y-
randomization test (response permutation test) was performed,
which estimates the robustness of models [31]. The X data are left
intact, whereas the Y data are permuted to appear in a different
order (random shuffling). A model is then fitted to the permuted Y-
data and the model statistics are computed for the derived model.
It is expected that the models from randomized activities would
have significantly lower accuracy values.
7. The applicability domain of models
An applicability domain (AD) of the model is needed to avoid
making predictions for compounds, which differ substantially from
the training set molecules. The AD is used to estimate which
compounds are suitable for model predictions and avoid
unjustified extrapolation of predictions. We used a method
introduced by Zhang et al. (2006) for defining the AD based on
the distribution of similarities between each compound and its
nearest neighbours in the training sets [32]. The AD was
calculated as follows:
AD~vdwzZs
The average of Euclidean distances between all points of the
training set were calculated from Similarity and Clustering Canvas
of Schro¨dinger modeling package [33], with 32 bit linear Daylight
fingerprint. Data for estimation of the Euclidean distance and
application of the AD on new compounds are available in
Files S2-S5. Then, using the distances lower than the average, a
new average distance ,d. and standard deviation s between
these distances were calculated. Z is an arbitrary parameter to
control the significance level and considerably affects the number
of compounds within the applicability domain. Increasing Z will
include compounds that are more dissimilar in the AD. We set the
value of Z to 0.7 to calculate the compounds within the AD of the
models in the foreign test set.
Results
1. PLS Regression Models
The linear regression model of log Vss and fu was attempted
with three descriptor sets: (1) 19 descriptors from ACDlabs and
MOE, (2) 121 descriptors from VolSurf+ and (3) 140 descriptors
from the combination of the two previous sets. The three sets were
first analyzed with PCA. In Table 2, the final PCA model statistics
for the three strategies are presented as well as the criteria of
selection chosen in each case. In Figure 3, the score plot of the
final PCA model of data set 3 is shown as an example. Similar
plots were obtained for the other data sets.
The statistical values of the final models are present in Figure 2.
Model 1 resulted in a non-predictive model, yielding a Q2Y
smaller than 0.50, and therefore the analysis of this set was not
taken any further. The final models were based on 332 compounds
and 9 descriptors from Volsurf+ (model 2) and 353 compounds and
11 descriptors combined from Volsurf+, ACDlabs and MOE (model
3). The PLS weight plot of model 3 is presented in Figure 4,
showing the relationships between the X-descriptors and Y-
responses, Vss and fu, at the same time. A detailed description of
PLS weight interpretation is presented in the legend. The final
equations for model 2 and model 3 are:
Model 2.
logVss~0:1521{0:1173L1LgSz0:2858L3LgS
{0:0123SOLYz0:0122LOGPn{Octz0:0463LgD9
{0:0083WN5{0:0002W1z0:2811ID3z0:0026A
fu~0:8134{0:0348L1LgSz0:1096L3LgSz0:0733SOLY
{0:0523LOGPn{Oct{0:0227LgD9z0:0005WN5
{0:0001W1z0:5579ID3{0:0272A
Model 3.
logVss~0:2464z0:0909LgS3{0:0269LgS10{0:0099 logS
z0:3894L3LgSz0:0465LgD10z0:0514ALogD5:5
z0:0010%FU10z0:0004MV{0:0005W1z0:0023D4
z0:0174HD
Table 4. Division of training and test set compounds into six classes according to observed Vss and fu.
Class 1a Class 1b Class 2a Class 2b Class 3a Class 3b Tota
Vss = 0–0.3 L/kg Vss = 0–0.3 L/kg Vss = 0.3–1 L/kg Vss = 0.3–1 L/kg Vss .=1 L/kg Vss .=1 L/kg l
& fu .0.7 & fu ,0.7 & fu .0.7 & fu ,0.7 & fu .0.7 & fu ,0.7
Training 18 87 22 68 38 149 382
Test 11 51 17 51 21 109 260
Total 29 138 39 119 59 258 642
doi:10.1371/journal.pone.0074758.t004
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fu~0:7052z0:0091LgS3{0:0024LgS10z0:0600 logS
z0:0277L3LgS{0:0153LgD10{0:0583ALogD5:5
z0:0009%FU10{0:0007MVz0:0001W1{0:0025D4
z0:0026HD
Where L1LgS and L3LgS are solubility profiling coefficients, logS
is the logarithm of solubility, LgS3 and LgS10 are the logarithms
of solubility at pH 3 and pH 10, respectively, SOLY is intrinsic
solubility, LOGP n-Oct is the partitioning coefficient in octanol/
water, LgD9, LgD10 and ALogD5.5 are distribution coefficients at
pH 9, pH 10 and pH 5.5, respectively, WN5 is hydrogen bond
acceptor volume, W1 is hydrophilic volume, ID3 is hydrophobic
integy moment, A is amphiphilic moment, %FU10 is % of fraction
unionized at pH 10 (not to be confused with fu), MV is molar
volume, D4 is hydrophobic volume and HD is hydrogen bond
donor.
Model 2 and model 3 were internally validated by cross-
validation, gaining Q2 values of 0.58 and 0.55, respectively. In
external validation of the models we determined their accuracy in
predicting log Vss and fu with the external test sets. In log Vss
prediction by model 2, two outliers were excluded (ribavirin and
bilobalide), while in fu prediction by model 2, four outliers
(acetylcysteine, amiodarone, aripiprazole, repaglinide) were ex-
cluded and in fu prediction by model 3, five outliers were excluded
(ethambutol, atovaquone, beclomethasone dipropionate, drota-
verine, irbesartan). The statistical results of the predictions are
presented in Figure 2. The Y-randomization test after 50
permutations provided R2Y- and Q2Y-intercepts smaller than
the recommended limits of 0.3 and 0.05 for both log Vss and fu,
respectively (data not shown).
The AD was estimated from the compounds belonging to the
training set as:
A~24:22zZ2:03
With Z = 0.7, AD is 25.641 that represent the maximum
distance between compounds in the training set and new
compound to be predicted. The compounds in the foreign test
set that fell inside this AD were selected, yielding a set of 35 drugs
for model 2, and 30 drugs for model 3. The statistical parameters
of log Vss and fu predictions for the foreign set are presented in
Table 5 and plots of the observed and predicted responses of
Figure 4. PLS weight plot of model 3. The plot illustrates the relationships between the eleven descriptors (in black) and Vss and fu (in red). The
dashed red line crosses the origo and the Vss response, and the continuous red line (perpendicular to the dashed line) represents the borderline
between negative and positive influences of the descriptors. The respective lines for fu are blue. Impact of descriptors is interpreted in the following
manner: the Vss descriptors that show orthogonal projection on the same side as Vss (on the right from red borderline) have positive impact on Vss,
and the descriptors on the left side of the borderline show negative impact on Vss. The farther away from the origo the projection of the descriptors
lies, the stronger is the impact on the corresponding response. As an example of the variables influence on Vss, two arrows have been drawn that
represent the orthogonal projections of variable LgS10 (negatively correlated to Vss) and %FU10 (positively correlated to Vss). Likewise, the
descriptors on the left side of blue borderline show positive impact on fu, and the descriptors on the right side of the borderline have negative
influence on fu.
doi:10.1371/journal.pone.0074758.g004
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model 3 and VolSurf+ ADME models are presented in Figure 5. A
comparison of the predicted and the observed values is found
Table S1. Increasing Z increases the number of compounds in the
foreign test set that are considered to be within the applicability
domain but decreases the accuracy of prediction due to inclusion
of dissimilar nearest neighbors (Figure 6).
2. RP Classification Models
The AUC for the in-bag training data for all trees in the forest
model is 0.96 and 0.92, and the out-of-bag AUC is 0.81 and 0.79
for the Vss and Vss & fu models, respectively. The in-bag results use
predictions for the records used to train the tree, while the out-of-
bag results use predictions for the left-out records. The statistics for
the training set data presented in Figure 2 are derived from the in-
bag results. The external test set including 260 compounds
(described in Methods section) was used to evaluate the predictive
ability of the two models. All compounds were classified according
to their Vss or Vss & fu values without applying AD. The overall
prediction accuracy, calculated as ROC curve, was 0.78 and 0.82,
respectively, and the sensitivity and specificity values are presented
Figure 5. Log Vss and fu prediction plots of model 3 versus VolSurf+ ADME models (Vd and protein binding). Dot lines represent 2-fold
error, dashed lines represent 3 –fold error and long dash lines represent 5-fold error. MFE: mean fold error.
doi:10.1371/journal.pone.0074758.g005
Table 5. Statistical parameters for log Vss and fu predictions
of the foreign set compounds inside the applicability domain
of the models, calculated with Z= 0.7.
Log Vss prediction of
foreign set fu prediction of foreign set
Qf
2 MFE % ,2-fold Qf
2 MFE %,2-fold
Model 2 0.62 2.85 60 0.59 5.58 54
Model 3 0.70 2.41 67 0.54 7.04 52
doi:10.1371/journal.pone.0074758.t005
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in Figure 2. The confusion matrices are presented in Tables S2-
S7.
In general, the sensitivity of the models is high for compounds
with a very low or high volume of distribution, while compounds
belonging to class 2, with Vss values between 0.3 and 1 L/kg are
more difficult to classify correctly. The Vss model performed well
on the training set, with sensitivity 0.79 in class 2, but less than half
of the class 2 compounds in the training set (42 of 93 compounds,
leading to a sensitivity of 0.45) were predicted to the correct class
in the out-of bag results (Table S3). Similarly, the model was able
to identify class 1 and class 3 compounds form the external test set
(sensitivity 0.71 and 0.81, respectively), while recognition of class 2
test set compounds was not as successful (sensitivity 0.32, Figure 2,
Table S6). Interestingly, in the Vss & fu model, compounds with
high fu were predicted more accurately, with 10 of 17 compounds
of the test set compounds correctly classified (sensitivity 0.59), but
only 7 of 51 compounds with low fu (sensitivity 0.14) (Figure 2,
Table S7). The Y-randomization test was performed four times,
and the AUC values for the model using the data set with
experimental Vss and Vss & fu values were significantly higher than
those obtained from the dataset with randomized values (data not
shown), indicating that our models are statistically robust. The AD
was applied to the test set and its effect analyzed on the Vss & fu
model (Figure 6). The prediction accuracy was highest with low Z
cutoff, as expected, and slowly decreasing as the cutoff was
increased to 1. However, increasing the cutoff from 1 to 20 did not
markedly affect the prediction accuracy, while increasing the
coverage of the test set from 39% to 100%. The small decrease in
prediction accuracy is probably due to the cluster-based approach
used to select the training and test set (described in Methods) that
make the chemical space covered by two set similar.
One aid for interpretation of forest models is a set of descriptor
importance measures, which indicate the relative importance of
the descriptors in distinguishing among the different classes in the
data. The percent selection frequency empirically appears to best
distinguish truly important descriptors from others. It represents
the percent of the time that the descriptor was selected for a split
when a split was possible. A summary of descriptors ranked as top
10 based on their frequency of occurrences in the models are given
in Table 6. It should be noted that size, polarity and lipophilicity
are predominant in all models. The simple importance measures
reported here are known to have bias in some cases [34].
However, if all descriptors have the same character as in our cases
(e.g. they are all continuous numerical properties), then bias is
generally not an issue.
Discussion
We have predicted Vss and fu with linear PLS models and
nonlinear RP classification models, aiming for models that rely on
in silico descriptors only and therefore are suitable for screening.
Vss is affected by the fu in plasma, and we wanted to explore if
predicting both parameters in parallel would help to find relevant
physicochemical descriptors affecting these parameters. PLS can
easily be used to correlate descriptors with several related
responses, but to our knowledge, this approach has not been used
in pharmacokinetic QSPR modeling.
The RP classification model was reasonably successful in
classifying compounds with high ($1 L/kg) or low (0–0.3 L/kg)
Vss, while it had difficulties to identify the compounds with
moderate (0.3–1 L/kg) Vss. Interestingly, the level of binding to
plasma proteins had an influence on the prediction accuracy,
which was seen most clearly in the moderate Vss class, where
compounds with high fu were correctly predicted in 59% of the test
set, but only 14% of those with low fu (Figure 2, Table S7). The
attempt to create a PLS model for Vss and fu (model 1) starting
with only 19 descriptors from ACDlabs and MOE was not
successful, but using a wider range of descriptors from Volsurf+
resulted in a predictive model (model 2) (Table 1 and Figure 2).
The combination of all descriptors to model 3 did not significantly
improve the prediction of the external set (Vss Qe
2 = 0.50, fu Qe
2
= 0.54) compared to model 2 (Vss Qe
2 = 0.52, fu Qe
2 = 0.51)
(Figure 2). However, model 3 had better success in predicting the
Vss of the compounds in the foreign set (model 3 Qf
2 = 0.70,
model 2 Qf
2 = 0.62) (Table 5). Notably, the prediction of the
compounds in the foreign set within the AD was better than for the
Figure 6. The effect of the AD on the prediction accuracy and chemical space coverage. Dashed black line: Q2 of the Vss foreign set
predicted with PLS model 3. Dashed purple line: percentage of compounds from the Vss foreign set predicted with PLS model 3. Black line: Q
2 of the
fu foreign set predicted with PLS model 3. Purple line: percentage of compounds from the fu foreign set predicted with PLS model 3. Dotted black
line: AUC of the test set predicted with RP classification. Dotted purple line: percentage of compounds from the test set predicted with RP
classification.
doi:10.1371/journal.pone.0074758.g006
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external set for both model 2 and 3. The AD was not used to filter
compounds for prediction in the external set, which might be one
reason for the improved performance on the foreign set. The use
of an AD prevents extrapolation beyond the limits of chemical
space that was used to build the model and can be used to identify
the compounds for which predictions are reliable.
The impact of the descriptors on the responses can be observed
graphically in the PLS weight plot (model 3 in Figure 4, model 2 in
Figure S1). In model 3, the descriptors L3LgS, %FU10 and
LgD10 have the highest positively correlated impact to Vss
(L3LgS, LogP n-oct and LgD9 in model 2, Figure S1), while LgS3,
D4, Molar Volume and ALogD5.5 have a more moderate positive
influence on Vss (A in model 2). LgS10 has the largest negative
correlation to Vss (L1LgS in model 2), while W1, HDonors and
LogS have smaller negative correlation in model 3 (Wn5, SOLY,
W1 and ID3 in model2). On the other hand, LogS, LgS3 and
LgS10 have the highest positive correlation with fu (SOLY in
model 2), while LogD10 and AlogD5.5 have the highest negative
correlation (LogD9 and LOGP n-Oct in model 2). All in all, this
suggests that charge and lipophilicity of the drug affect drug
distribution, albeit with an inverse relationship. Thus, the
lipophilicity descriptors have high correlation with the two
responses, positive with Vss and negative with fu, while reversely,
the charge and solubility descriptors have negative correlation with
Vss and positive with fu. There is a complex relationship between fu
and Vss and increasing the fu of a compound does not inevitably
lead to a higher volume of drug distribution, as is stated in many
pharmacokinetic textbooks [35], [36]. This is easy to understand,
since structural changes influencing the drugs ability to bind to
plasma proteins may also affect the tissue binding of the drug.
Similar descriptors were found to be important in both the RP
classification models (Table 6) and the PLS models. These include
solubility descriptors, LogD at pH 9 or 5, as well as hydrophilic
and hydrophobic area and volume descriptors. Due to the
complexity of Vss and fu, many descriptors were always required
to yield good prediction capability. Previously, trends have been
observed between Vss and LogP, polar surface area and hydrogen
bond descriptors for the data set we have used [18]. Using the
same data set, Berellini et al. (2009) found hydrogen bonding,
LogD at pH 5–10, flexibility of the molecule and the Volsurf+
descriptors DRDRDO, DRDRAC to be important in their Vss
model [12]. DRDRDO and DRDRAC are pharmacophoric
descriptors of the maximum area of the triangles derived from Dry
(DR), H-bond acceptor (AC) and H-bond donor (DO) points in a
molecule. DRDRDO and flexibility were among the ten most
influential descriptors in the RP models, but in the PLS models
they did not have equally high importance. However, when
comparing our descriptor selection to previous models of Vss it
must be kept in mind that we have modeled both Vss and fu
parameters. Therefore a comparison is not directly applicable as
descriptors having high influence on one parameter, but no
correlation with the other parameter, are likely to be removed in
our models.
Outliers are usually interesting, and the analysis of outliers can
sometimes give a deeper understanding of the mechanisms under
investigation. However, it is difficult to analyse the outliers in this
study, because we do not know the reason for their exceptional
behavior. Deviations in Vss may be due to the active transport
(influx or efflux) or compound specific binding to the tissues. As an
example, let’s consider the outliers in the prediction of Vss by the
PLS models (ribavirin, bilobalide, tamsulosin, decitabine). Riba-
virin and decitabine are substrates of widely expressed nucleoside
transporters, and extensive active transport might lead to outlier
profiles of ribavirin and decitabine [37]. Tamsulosin is a substrate
of alpha1 adrenergic receptors and bilobalide binds to GABA,
glycine, and 5-HT3 receptors [38]. We cannot be sure, however, if
these transport and binding phenomena take place substantially
enough to cause exceptional Vss values. Clearly, Vss and fu are
complex phenomena that are affected by numerous factors.
Therefore, explanations for the outlier behavior are not on firm
ground and the reasons can be identified only by extensive
experimental work.
We compared the performance of our model 3 with the volume
of distribution and plasma protein binding models available in the
Volsurf+ package (Figure 5). As no AD is reported for the Volsurf+
models, we have applied our AD with the Z cutoff value of 0.7 to
select the compounds from the foreign test set for both models. For
the practical use of AD in Vss and fu prediction, see File S2. It
should be noted that we are not aware of which compounds have
been used to train the Volsurf+ model, and it is possible that some,
or all, of the compounds used in our test set have been used to for
that purpose. The same considerations apply for the Volsurf+
plasma protein binding model. Our model achieved higher
accuracy than the Volsurf+ model in predicting fu (Qf2 = 0.54 and
Table 6. Most influential descriptors in the classification models.
Vss Vss and fu
Descriptor Type
Number of
Chances
Percent
Selection
Frequency Descriptor Type
Number of
Chances
Percent Selection
Frequency
Rule Of 5 Drug like 12 8.3 PSAR Polar area 4 25
CD3 Hydrophobic area 31 6.4 Num Rings Topology 5 20
FLEX_RB Size/Shape 69 5.8 W8 Hydrophilic area 5 20
L1LgS Solubility 53 5.7 R Size/Shape 10 10
CD6 Hydrophobic area 37 5.4 DRDRDO Pharmacoforic 12 8.3
CW8 Hydrophilic area 20 5 D8 Hydrophobic area 26 7.7
LgS11 Solubility 66 4.5 LgD9 LogD 32 6.3
C ratio Topology 45 4.4 ALogD5 LogD 34 5.9
NO ratio Topology 48 4.2 CP Shape 17 5.9
LgS5 Solubility 72 4.2 AUS7.4 Charge 35 5.7
doi:10.1371/journal.pone.0074758.t006
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Qf
2 = 0.38, respectively) (Figure 5), while the prediction of Vss was
comparable to the Volsurf+ model (Vss Qf2 = 0.70 and Qf2 = 0.71
for model 3 and Volsurf+ models, respectively). The best
predictions with our model were obtained at fu values above
0.05. Predictions of the compounds with fu values above 0.05 in
the foreign set had a MFE of only 2.2 for model 3, compared to
7.04 for the whole foreign set (Figure 5, table 5). The predictions at
fu values below 0.05 give high FE values (.5-fold), whereas %
error in this region is low. However, FE is pharmacologically a
more relevant parameter, because the free drug concentration in
plasma, Cu, is defined as fu x C. Therefore, 3-fold change in fu is
expected to result in 3 fold change in Cu Unfortunately, we do not
have an explanation for the poor results for the compounds that
have very low fu values, however, the compounds that were badly
predicted by our models were also badly predicted by the Volsurf+
model (Table S1), suggesting that the exceptional behavior is drug
dependent and not due to the model.
The physical complexity of the Vss and fu parameters makes
their prediction very challenging, and we were not able to reach
models with optimal predictability. One way to improve predic-
tion accuracy is to build the model using a narrower range of more
similar compounds. We divided the data set of 642 compounds
based on structural features or chemical properties and used these
data sets to build several sub-models. However, the models were
not able to achieve much higher accuracy than the more global
models presented here (data not shown), but presented a much
narrower AD and therefore more limited use.
Conclusions
The PLS models of Vss showed similar performance to the
commercial Volsurf+ model, while the fu prediction accuracy was
slightly better. The RP classification models were able to
distinguish between compounds with high or low Vss values, but
accurate classification of moderate Vss or of low fu values were not
as successful. Due to the complex nature of Vss and fu parameters,
a fairly large number of descriptors were needed for meaningful
models. The advantages of the models compared to previous
models is that they are based on a large set of structurally
unrelated compounds, they are open, and they have a defined AD,
which aids in identifying compounds for which reliable predictions
can be made.
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